Xeris Pharmaceuticals Inc. (NASDAQ: XERS) shares are -33.26% down in the year-to-date (YTD) period and have moved 10.71% or $0.45 higher in the latest trading session. However, stock’s trailing 12-month performance remains nearly +231.34% lower. Comparatively, the stock is -35.01% down YTD and -1.36% over the trailing 3-month period. If we look at the shorter duration, its week performance is 25.80% and 64.51% over the month.
On July 16, 2018, RBC Capital Mkts recommended the XERS stock is a Outperform, while earlier, Piper Sandler had Initiated the stock as a Overweight on February 18, 2020. 5 analysts offering the recommendations for the stock have a consensus rating of 1.60 to suggest that the XERS stock is a “Strong Buy. 0 of the 5 analysts rate the stock as a “Sell”, while 0 has rated it as “Underweight”. 5 recommend buying, with 0 rating it as an Overweight.
The stock currently trades at $4.70. The forecasts give the Xeris Pharmaceuticals Inc. stock a price target range of $14.00 on the higher side while at least one analyst think the stock could plunge to a low of $7.00. The two limits represent an upside potential of 66.43% or 32.86%.
Analysts estimate the earnings to increase 13.70% in the current quarter to -$0.56, up from the -$1.22 reported in the same quarter a year ago. For the current year, earnings should grow to an average of -$2.6, up 439.30% from -$4.81 reported last year. Analysts also offered guidance for the next financial quarter, with their average projected EPS at between -$0.73 and -$0.44. Wall Street estimates earnings per share to be at an average of -$1.72 for the next year.
Insider Transactions Summary
According to SEC data, total insider shares purchases at the company stands at 23 over the last 12 months, while SEC filings reveal that there have been 4 insider sales over the same period. Insiders have purchases 526,069 shares while those sold by company executives and officers stand at 47,301. The last 3 months have seen insiders trade a total of 11,968 and 0 in purchases and sales respectively.
Shannon John Patrick Jr, bought 7,886 shares worth $25219.0 at $3.20 per share on May 08. The insider had earlier bought another 22,000 XERS shares valued at $77994.0 on May 13. The shares were bought at $3.55 per share. Edick Paul R bought 33,000 shares at $3.00 per share on May 08 for a total of $99000.0 while Hecht Beth, bought 4,000 shares on Mar 13 for $7880.0 with each share fetching $1.97.
AIM ImmunoTech Inc. (AMEX:AIM), on the other hand, is trading around $2.25 with a market cap of $90.74M and analyst research firms have a negative stance on its shares. Some analysts are even forecasting -$0.43 per share in earnings this year on a short term (1 year) basis.
Let us briefly look at the AIM ImmunoTech Inc. (AIM) financials, with a focus on its operating details as indicated in its earnings report for the last quarter.
Company balance sheet and cash flow
AIM’s operating expenses over the recent quarter were at $3.38 million. This represented a -8350.0% of the company’s total revenues which amounted $40000.0. With this in place, we can see that the company’s diluted EPS declined -$0.11 on the year-over-year period, shrinking to -$1.07 as given in the last earnings report.
In terms of the balance sheet & cash flow as of (Sep 2020), the total assets figure advanced to $50.12 million from $42.41 million over the previous quarter. Short term investments amounted to $1.09 million while total current assets were at $35.16 million. The cash flow from operating activities totaled -$4.53 million, significantly lower than the -$4.23 million reported in the year-ago quarter. The company’s free cash flow for the quarter was -$4.53 million.
Insiders have transacted a total of 1 times at AIM ImmunoTech Inc. over the last 6 months, with insider purchases undertaken 1 times and accounting for 10,730 shares. Insider sales totaled 0 shares over the same period, with these deals completed in 0 transactions. Looking at these numbers, we realize that net purchases over that period are 1.0 shares. Insiders now hold a total of 793.01k shares after the latest sales, with 1.40% net shares purchased.
Insiders own 0.40% of the company shares, while shares held by institutions stand at 4.70% with a share float percentage of 39.26M. Investors are also buoyed by the number of investors in a company, with AIM ImmunoTech Inc. having a total of 18 institutions that hold shares in the company. The top two institutional holders are Morgan Stanley with over 0.48 million shares worth more than $1.18 million. As of Jun 29, 2020, Morgan Stanley held 1.20% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the investment firm holding over 0.48 million shares as of Jun 29, 2020. The firm’s total holdings are worth over $1.18 million and represent 1.20% of shares outstanding.